

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 09/990,595
Filed: November 21, 2001

Claims 90-107

90. A hybridoma cell line selected from the group consisting of 3F5.4G6 having ATCC accession number HB12060, 3D7-1.I having ATCC accession number HB12309, 4E10 1.14 having ATCC accession number HB12310, 3E11 (ATCC HB12488), 4D8 (ATCC HB12487), 3E6 (ATCC HB12486), 3C9 (ATCC HB12484), 2C7 (ATCC HB 12490) 1G3, (ATCC HB 12489) 3C4 (ATCC HB 12494), 3C6, (ATCC HB12491), 4D4 (ATCC HB12493), 1G9 (ATCC HB12495) 5C8B9 (ATCC HB12492) and 3G6 (ATCC HB12485).
91. A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG.1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, which in said second antibody is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB 12492).
92. A kit for diagnosis, prognosis, or monitoring prostate cancer, comprising the monoclonal antibody according to claim 91 or an antigen binding fragment thereof.
93. The kit according to claim 92 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 09/990,595
Filed: November 21, 2001

94. A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060) 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB 12492).
95. The monoclonal antibody of claim 94, which is produced by a hybridoma selected from the group consisting of 3F5.4G6 (ATCC HB12060), 1G3 (ATCC HB12489), and 4C8B9 (ATCC HB 12492).
96. A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostatic specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG.1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3D7-1.1 (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).
97. A kit for diagnosis, prognosis or monitoring prostate cancer, comprising the monoclonal antibody according to claim 96 or an antigen binding fragment thereof.
98. A kit according to claim 97 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.
99. A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 09/990,595
Filed: November 21, 2001

consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).

100. The monoclonal antibody of claim 99, which is produced by a hybridoma selected from the group consisting of 3D7-1.1, (ATCC HB12309), 4E10-1.14 (ATCC HB12310), 3C9 (ATCC HB12484) and 2C7 (ATCC HB12490).

101. A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostate specific membrane antigen, said domain comprising the amino acid sequence from residue #44 to 750 as depicted in FIG.1 (SEQ ID NO:2), the antigen-binding region of which competitively inhibits the immunospecific binding of a second monoclonal antibody to its target epitope, wherein said second antibody is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB 12493), and 1G9 (ATCC HB12495).

102. A kit for diagnosis, prognosis, or monitoring prostatic cancer, comprising the monoclonal antibody according to claim 101, or an antigen binding fragment thereof.

103. The kit according to claim 102 in which the antibody or antigen binding fragment thereof is packaged in an aqueous medium or in lyophilized form.

104. A monoclonal antibody having an antigen-binding region of an antibody produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB 12493), and 1G9

Applicants: Ron S. Israeli et al.
U.S. Serial No.: 09/990,595
Filed: November 21, 2001

(AT HB12495).

105. The monoclonal antibody of claim 104, which is produced by a hybridoma selected from the group consisting of 3C6 (ATCC HB12491), 4D4 (ATCC HB 12493), and 1G9 (AT HB12495).
106. A monoclonal antibody having an antigen-binding region specific for the extracellular domain of prostatic specific membrane antigen.
107. A monoclonal antibody having an antigen-binding region specific for the outer membrane domain of prostatic specific membrane antigen.